Constitutive and cytokine-mediated activation of PI3K/Akt/mTOR signaling pathway is a common feature in AML patients, and inhibition of this pathway is a viable therapeutic strategy in the treatment of AML [36]. The gene discussed is MTOR; the disease is acute myeloid leukemia.